A reduction in mTORC1 activity may also underlie the proposed beneficial effect of inhibiting neuregulin‐1 (NRG1) type III signaling in similar neuropathy models (Bolino et al., 2016), although the role of NRG1 signaling in neuropathies is complex (Fledrich et al., 2014). Here, SGCG is linked to neuropathy.